logo
  

AbbVie's Risankizumab Gets CHMP Positive Opinion For Active Psoriatic Arthritis Treatment

AbbVie (ABBV) said that the European Medicines Agency's or EMA Committee for Medicinal Products for Human Use or CHMP recommended the approval of Risankizumab (SKYRIZI) alone or in combination with methotrexate (MTX), for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs.

SKYRIZI is 150 mg, subcutaneous injection at week 0, week 4 and every 12 weeks thereafter.

The CHMP positive opinion is a scientific recommendation for marketing authorization to the European Commission, which authorizes marketing approval in the European Union.

If the CHMP recommendation is accepted by the European Commission, this will mark the second indication for risankizumab in the European Union, which was approved in 2019 for the treatment of adult plaque psoriasis.

The Marketing Authorization will be valid in all member states of the European Union, as well as Iceland, Liechtenstein, Norway and Northern Ireland.

Risankizumab (SKYRIZI) is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading development and commercialization globally.

Use of risankizumab in psoriatic arthritis is not approved and its safety and efficacy are under evaluation by regulatory authorities.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Twitter Inc. said it is expanding engineering center in Singapore, its Asia Pacific headquarters. The number of engineers there will be doubled to over 100 staff in 2023. Focused on product innovations and improvements, the new hires will work from Singapore on global initiatives for Twitter. These new technical hires will span roles in engineering, data science, machine learning and product... The U.S. Food and Drug Administration (FDA) has granted approval and reissued the revised Emergency Use Authorization (EUA) to Gilead Sciences Inc. for antiviral drug Veklury (remdesivir) to treat certain non-hospitalized adults and pediatric patients with mild-to-moderate COVID-19 disease. Shares of Philips Electronics NV were losing more than 4 percent in the morning trading in Amsterdam as well as in pre- market activity on the NYSE, after the Dutch consumer electronics giant reported lower profit and sales in its fourth quarter. Comparable sales declined, while comparable order intake increased. Further, the company maintained its dividend, and said it expects to start the year
Follow RTT